维甲酸协同砷剂治疗急性早幼粒细胞白血病的机制进展

摘要
图/表
参考文献(28)
相关文章 (15)

全文: PDF (635 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要急性早幼粒细胞白血病（APL）是急性髓细胞白血病的一种特殊亚型。目前APL患者的首选治疗方案是维甲酸（RA）协同砷剂。近5年来，RA协同砷剂治疗APL的机制在分子生物学和细胞遗传学方面出现一些新的研究成果。本文主要从额外基因的改变、非基因的分子机制、联合药物的机制、佐剂和载体等进行阐述，从而为今后的基础研究提供参考。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	刘冯董敏肖丁华

关键词 ：急性早幼粒细胞白血病, 维甲酸, 砷剂, 机制

Abstract：Acute promyelocytic leukemia (APL) is a special subtype of acute myeloid leukemia. The first-line treatment for APL patients is retinoic acid (RA) combined with arsenic at present. There has been some new research achievement about the mechanism of RA and arsenic in the treatment of APL appeared in molecular biology and cytogenetics in the past five years. This article mainly describes the changes of additional genes, non-genetic molecular mechanisms, mechanisms of combined drug, adjuvants and carriers, so as to provide a reference for future basic research.

Key words： Acute promyelocytic leukemia Retinoic acid Arsenic Mechanism

基金资助:国家自然科学基金资助项目（81560032）；
桂林市科学研究与技术开发计划项目（2016012706-13）；
广西高校中青年教师基础能力提升项目（KY2016LX226）。

作者简介: 刘冯（1975.11-），男，硕士，副主任医师；研究方向：血液病。

引用本文:

刘冯董敏肖丁华. 维甲酸协同砷剂治疗急性早幼粒细胞白血病的机制进展[J]. 中国医药导报, 2020, 17(30): 45-48.
LIU Feng DONG Min XIAO Dinghua. Mechanism of Retinoic acid combined with arsenic in the treatment of acute promyelocytic leukemia. 中国医药导报, 2020, 17(30): 45-48.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2020/V17/I30/45

[1] Abedin S，Altman JK. Acute promyelocytic leukemia：preventing early complications and late toxicities [J]. Hematology Am Soc Hematol Educ Program，2016，（1）：10-15.
[2] McCulloch D，Brown C，Iland H. Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia： current perspectives [J]. Onco Targets Ther，2017，10（3）：1585-1601.
[3] Cicconi L，Lo-Coco F. Current management of newly diagnosed acute promyelocytic leukemia [J]. Ann Oncol，2016，27（8）：1474-1481.
[4] O′Donnell MR，Tallman MS，Abboud CN，et al. Acute Myeloid Leukemia， Version 3.2017， NCCN Clinical Practice Guidelines in Oncology [J]. J Natl Compr Canc Netw，2017，15（7）：926-957.
[5] 中华医学会血液学分会，中国医师协会血液科医师分会.中国急性早幼粒细胞白血病诊疗指南（2018年版）[J].中华血液学杂志，2018，39（3）：179-183.
[6] Shen Y，Fu YK，Zhu YM，et al. Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide [J]. EBioMedicine，2015，2（6）：563-571.
[7] Wang LN，Tang YL，Zhang YC，et al. Arsenic trioxide and all-trans-retinoic acid selectively exert synergistic cytotoxicity against FLT3-ITD AML cells via co-inhibition of FLT3 signaling pathways [J]. Leuk Lymphoma，2017，58（10）：2426-2438.
[8] Esnault C，Rahmé R，Rice KL，et al. FLT3-ITD impedes retinoic acid，but not arsenic，responses in murine acute promyelocytic leukemias [J]. Blood，2019，133（13）：1495-1506.
[9] 李娜，窦春慧，管浩然，等.维甲酸联合亚砷酸治疗伴FLT3-ITD突变的APL患者的预后分析[J].临床血液学杂志，2019，32（5）：687-692.
[10] Harinder SG，Rita Y，Cyrus RK，et al. Oral Arsenic Trioxide，All-Trans Retinoic Acid，and Ascorbic Acid Maintenance After First Complete Remission in Acute Promyelocytic Leukemia：Long-term Results and Unique Prognostic Indicators [J]. Cancer，2020，10（5）：1002.
[11] Baba SM，Shah ZA，Pandith AA，et al. Influence of bcr-3 PML-RARα transcript on outcome in Acute Promyelocytic Leukemia patients of Kashmir treated with all-trans retinoic acid and/or arsenic trioxide [J]. Cancer Genet，2019，231-232：14-21.
[12] Tao S，Wang C，Chen Y，et al. Long-term effect of all-trans retinoic acid and arsenic trioxide sequential maintenance in patients with acute promyelocytic leukemia [J]. Leuk Lymphoma，2019，60（3）：711-719.
[13] Liu X，Chen J，Yu S，et al. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells [J]. Cell Death Dis，2017，8（5）：e2782.
[14] Zhang X，Pan J. Resistance to arsenic trioxide and retinoic acid therapy in acute promyelocytic leukemia [J]. Ann Hematol，2017，96（4）：707-708.
[15] Kozono S，Lin YM，Seo HS，et al. Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells [J]. Nat Commun，2018，9（1）：3069.
[16] Huynh TT，Sultan M，Vidovic D，et al. Retinoic acid and arsenic trioxide induce lasting differentiation and demethylation of target genes in APL cells [J]. Sci Rep，2019，9（1）：9414.
[17] Jambrovics K，Uray IP，Keillor JW，et al. Benefits of Combined All-Trans Retinoic Acid and Arsenic Trioxide Treatment of Acute Promyelocytic Leukemia Cells and Further Enhancement by Inhibition of Atypically Expressed Transglutaminase 2 [J]. Cancers：Basel，2020，12（3）：648.
[18] Chen X，Wang F，Zhang Y，et al. A novel NPM1-RARG-NPM1 chimeric fusion in acute myeloid leukaemia resembling acute promyelocytic leukaemia but resistant to all-trans retinoic acid and arsenic trioxide [J]. Br J Cancer，2019，120（5）：1023-1025.
[19] Gao N，Wang XX，Sun JR，et al. Clinical impact of galectin-3 in newly diagnosed t（15；17）（q22；q21）/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens [J]. Ann Hematol，2017，96（5）：711-718.
[20] Hu J，Sun Q，Fang W，et al. Effect of combination of all-trans retinoic acid and arsenic trioxide on apoptosis of acute promyelocytic leukemia cells [J]. Cell Mol Biol，2019， 65（4）：97-100.
[21] Masciarelli S，Capuano E，Ottone T，et al. Retinoic Acid and Arsenic Trioxide Sensitize Acute Promyelocytic Leukemia Cells to ER Stress [J]. Leukemia，2018，32（2）：285-294.
[22] Burnett AK，Russell NH，Hills RK，et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups （AML17）：results of a randomised，controlled，phase 3 trial [J]. Lancet Oncol，2015，16（13）：1295-1305.
[23] Abaza Y，Kantarjian H，Garcia-Manero G，et al. Long-term outcome of acute promyelocytic leukemia treated with all trans retinoic acid，arsenic trioxide，and gemtuzumab [J]. Blood，2017，129（10）：1275-1283.
[24] Zhang X，Zhang H，Chen L，et al. Arsenic trioxide and all-trans retinoic acid（ATRA）treatment for acute promyelocytic leukemia in all risk groups：study protocol for a randomized controlled trial [J]. Trials，2018，19（1）：476.
[25] Jung YS，Cheong HJ，Kim SJ，et al. Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide [J]. Leuk Res，2014，38（8）：977-982.
[26] Farzaneh A，Ray ML，Joanne LD，et al. Fucoidan Enhances the Therapeutic Potential of Arsenic Trioxide and All-Trans Retinoic Acid in Acute Promyelocytic Leukemia，in vitro and in vivo [J]. Onco target，2016，7（29）：46028-46041.
[27] Patel S，Guerenne L，Gorombei P，et al. pVAX14DNA-mediated Add-On Immunotherapy Combined With Arsenic Trioxide and All-Trans Retinoic Acid Targeted Therapy Effectively Increases the Survival of Acute Promyelocytic Leukemia Mice [J]. Blood Cancer J，2015， 5（12）：e374.
[28] Fan J，He Q，Wang Z，et al. Self-Assembled Nanocomplex for Co-Delivery of Arsenic-Retinoic Acid Prodrug into Acute Promyelocytic Leukemia Cells [J]. J Biomed Nanotechnol，2018，14（6）：1052-1065.